Anti-Mullerian Hormone serum levels remain stable under cross-sex hormone therapy of transgender men

Although successful pregnancies carried by transgender men have been reported, long-term effects of testosterone therapy on fertility remain unknown. [ view full abstract ]

Although successful pregnancies carried by transgender men have been reported, long-term effects of testosterone therapy on fertility remain unknown.

To study markers of ovarian reserve during testosterone therapy. [ view full abstract ]

To study markers of ovarian reserve during testosterone therapy.

Prospective open-label study of transgender men prior and during treatment with IM Testoviron Depot 250 mg q3 weeks. Sampling was conducted in the follicular phase at baseline and 10 days after injection three and 12 months... [ view full abstract ]

Prospective open-label study of transgender men prior and during treatment with IM Testoviron Depot 250 mg q3 weeks. Sampling was conducted in the follicular phase at baseline and 10 days after injection three and 12 months subsequently.

Anti-mullerian hormone (AMH) serum levels; endometrial thickness and antral follicular count determined by pelvic US. [ view full abstract ]

Anti-mullerian hormone (AMH) serum levels; endometrial thickness and antral follicular count determined by pelvic US.

Thirty five subjects (mean age 24±5.9 y) were included. Preliminary results of twenty two patients with at least one follow up visit are reported. AMH levels were within the normal range (5.8±2.9 ng/ml) and did not change... [ view full abstract ]

Thirty five subjects (mean age 24±5.9 y) were included. Preliminary results of twenty two patients with at least one follow up visit are reported.

AMH levels were within the normal range (5.8±2.9 ng/ml) and did not change significantly after three (5.3±2.4 ng/ml, N=22) and 12 months of treatment (4±2.2 ng/ml, N=8). As expected, testosterone levels increased (0.57±0.7, 6 ±3.2 ,6.6±2.8 ng/ml; p<0.0001) and estradiol levels decreased (187±184 , 57±15, 54.8 pg/ml; p=0.012) after three and 12 months respectively. There was a modest but significant decrease in LH levels (7.7±5, 4.2±3.4,3.9± 2.8 mIU/ml, p=0.022), but FSH levels (4.1±1.7, 4.4±2.2, 4.7±1.8 mIU/ml), as well as endometrial thickness (7.2±3.9, 5.3±1.2, 5±3.3 mm)remained unchanged. In all but twostudies, multiple ovarian small follicles were detected by pelvic sonography.

AMH levels remain stable during short term testosterone treatment. Further, there is no suppression of the hypothalamo-pituitary-gonadal axis and ovarian folliculogenesis is maintained. Longer follow up is needed for... [ view full abstract ]

AMH levels remain stable during short term testosterone treatment. Further, there is no suppression of the hypothalamo-pituitary-gonadal axis and ovarian folliculogenesis is maintained. Longer follow up is needed for assessment of testosterone effects on fertility potential.